Mantle Cell Lymphoma (MCL)

Mantle Cell Lymphoma (MCL) is the indication for 7 drugs in DrugBank. It is covered by 9 curated, structured indications.

Also known as: Lymphoma, Mantle-Cell · Mantle Cell Lymphoma · Lymphoma, Mantle Cell · Mantle-Cell Lymphoma · B-cell Mantle Cell Lymphoma
Classified under: Hemic and Lymphatic Diseases
Immunoproliferative Disorders
Lymphatic Disorders
Neoplasms
Indicated drugs: Acalabrutinib
Bendamustine
Bortezomib
Chlorambucil
Lenalidomide
Rituximab
Zanubrutinib

Resolves to

Vocabularies

MeSHM0328571ICD-10C83.1SNOMED CT155444003MedDRA10026798UMLSC0026691

What you can answer from here — as of November 13, 2026

7Indicated drugsWith each drug's targets and mechanism

Listed above

9Structured indicationsPopulation, line of therapy, route and combination as fields, not prose

1,136Clinical trialsPhase, status and sponsor resolved per trial

6Drugs reporting it as an adverse effectWith incidence where the label states it

Which approved drugs for Mantle Cell Lymphoma (MCL) share a target, and which companies have late-stage candidates against it?

Create a free account or log in to explore the full data card.